Of note, galantamine, a tertiary alkaloid first isolated from Galanthus nivalis L. (Amaryllidaceae), is currently included in the AD therapy for its cholinesterase inhibitory properties and its ability to enhance the cholinergic function and ameliorate memory deficits (Heinrich, 2010; Anand and Singh, 2013). This evidence concerns the gene BCHE and Alzheimer disease.